Athenex Annual Revenue, Number of Employees, Growth and Funding
Estimated Revenue & Financials
- Athenex's estimated annual revenue is currently $42M per year.
- Athenex received $100.0M in venture funding in July 2018.
- Athenex's estimated revenue per employee is $187,540
- Athenex's total funding is $252M.
- Athenex has 224 Employees.
- Athenex grew their employee count by 9% last year.
- Athenex currently has 42 job openings.
|James Hussey||Executive Vice President|
|Leanne Kisicki||Director Of Quality Control|
|Sameer Urgaonkar||Associate Director of Chemistry|
|James Clements||Director of Project Management|
|David Cutler||VP Clinical Development|
|Karen Gatewood||Director, Corporate Contracting|
|Ann Choi-Roloff||Area Sales Director|
|Tony Gulczynski||Vice President Alternative Customer Channels|
|Jonathan Turnquest||Director of Supply Chain & Logistics|
|Ulziihutag Darambazar||Director of Commercial Analytics|
What Is Athenex?
Athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. The company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. Our business includes medical technology innovation centers and a unique manufacturing supply chain across both China and North America. Through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
BUFFALO, N.Y., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the ...
On Thursday, shares of Athenex, Inc. (NASDAQ:ATNX) marked $14.65 per share versus a previous $14.09 closing price. With having a 3.97% ...
Athenex reported positive results in a phase 3 study using oral paclitaxel to treat patients with metastatic breast cancer. The key advantage of ...
|2018-01-23||$Undisclosed||Undisclosed||Deutsche Bank Securities||Article|
|2018-01-26||$75.4M||Undisclosed||Deutsche Bank Securities||Article|
Athenex Executive Hires
|2016-02-10||Simon Pedder||VP Corporate Strategy/Business Development||Article|
|2016-04-05||David Cutler||VP Clinical Development||Article|
|2016-07-11||James Hussey||EVP Pharmaceutical Division||Article|
|2017-02-28||Nick Riehle||Chief Financial Officer||Article|
|2018-06-06||Christina Wang||VP Clinical Operations and Corporate Development, Asia Pacific.||Article|